New Analyst Forecast: $ELV Given $500.0 Price Target

Truist Financial set a $500 price target for ELV, while the median target from two analysts over the last six months is $482.5. Congressional members have traded ELV stock 9 times in the past six months, with sales outpacing purchases, while insiders have sold shares in three transactions. Institutional investors displayed mixed sentiment in Q1 2025, with Capital International Investors adding 1,675,257 shares, while PRICE T Rowe Associates reduced their holdings by 1,475,499 shares.

Analysis

Elevance Health (ELV) exhibits a mixed signaling environment. Analyst coverage includes a recent price target of $500.0 set by Truist Financial, contributing to a median target of $482.5 from two analysts over the last six months. This generally positive analyst outlook is contrasted by selling activity from insiders and members of Congress. Specifically, ELV insiders conducted three sales transactions in the past six months with no open market purchases, including sales by the EVP & CFO (4,588 shares for ~$1.95 million), EVP & President, Commercial (3,504 shares for ~$1.39 million), and CAO & Controller (443 shares for ~$184k). Congressional trading data over the same period shows nine trades in ELV stock, comprising two purchases and seven sales. Institutional activity in Q1 2025 was also divided: 847 institutional investors added ELV shares while 871 decreased their positions. Notable increases include Capital International Investors adding 1,675,257 shares (+43.2%) and Bank of America Corp /DE/ adding 878,855 shares (+66.3%), while PRICE T Rowe Associates Inc /MD/ reduced holdings by 1,475,499 shares (-13.9%) and FMR LLC cut 648,144 shares (-29.6%). The overall sentiment score for ELV is moderately negative (-0.5), reflecting these divergent signals.

Key Decisions for Investors

• Investors should weigh the constructive analyst price targets against the notable selling patterns observed among company insiders and members of Congress.
• The divergent institutional investor activity, with significant new stakes and divestitures, suggests a lack of clear consensus; monitoring future institutional holding reports for directional shifts is advisable.
• Given the insider sales and overall negative sentiment signals, a cautious approach may be warranted until further fundamental developments or market sentiment shifts provide a clearer outlook for ELV.